Approval · Notice of Compliance 35749 · 2025
AVALIDE: Notice of Compliance 35749
Issued July 25, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35749
- Date
- July 25, 2025
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Product Monograph reformatted to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVALIDE | Not yet assigned | — |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- IRBESARTAN 150 MG per TAB
- IRBESARTAN 300 MG per TAB